AI Insight
This pooled analysis of individual participant data examined finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in patients with chronic kidney disease (CKD). The study found that finerenone significantly reduced the risk of CKD progression, including kidney failure, and decreased hospitalizations for heart failure, cardiovascular death, and all-cause mortality. These benefits were consistent across patients with varying disease causes, blood sugar levels, kidney function measurements, and protein levels in urine.
Why it matters
The findings suggest finerenone could become a core treatment option for a broad spectrum of CKD patients, potentially improving kidney outcomes and reducing cardiovascular complications in a population at high risk for both. This expands treatment options beyond traditional therapies for patients with declining kidney function.
In the studied populations with CKD, finerenone reduced the risk of CKD progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death. These findings support finerenone as a foundational therapy for CKD across a broad range of disease aetiologies and levels of glycaemia, eGFR, and albuminuria.